NEW YORK, Nov. 6, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (OTCBB:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced that Michael Weiss, the Company’s Executive Chairman and Interim Chief Executive Officer, will participate in the Brean Capital 2012 Life Sciences Summit held on Wednesday November 7, 2012 at the Sentry Centers in New York City. This conference will feature small group sessions as well as one on one meetings with institutional clients.
